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Background: Storage symptoms, associated with benign prostatic hyperplasia (BPH), often co-exist with voiding
symptoms in men with lower urinary tract symptoms (LUTS). Storage symptoms are likely to be most bothersome, and
may not be adequately resolved by treatment with α-blocker or antimuscarinic monotherapy. A recent randomised
controlled phase 3 trial (NEPTUNE) demonstrated that a fixed-dose combination (FDC) of solifenacin 6 mg plus an oral
controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg) improved storage symptoms, as well as
quality of life, compared with TOCAS alone in men with moderate-to-severe storage symptoms and voiding symptoms.
This analysis aimed to assess the cost-effectiveness of a FDC tablet of solifenacin 6 mg plus TOCAS relative to tolterodine
plus tamsulosin given concomitantly, from the perspective of the UK National Health Service (NHS).
Methods: A Markov model was developed for men aged ≥45 years with LUTS/BPH who have moderate-to-severe
storage symptoms and voiding symptoms. The model calculated cost-effectiveness over an analytical time horizon of
1 year and estimated total treatment costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratio.
Results: The FDC tablet of solifenacin 6 mg plus TOCAS was associated with lower total annual costs (£860 versus £959)
and increased QALYs (0.839 versus 0.836), and was therefore dominant compared with tolterodine plus tamsulosin. Time
horizon, discontinuation or withdrawal rates, drug cost and utility values were the main drivers of cost-effectiveness. The
probability that the FDC tablet of solifenacin 6 mg plus TOCAS is cost-effective was 100% versus tolterodine plus
tamsulosin, at a willingness-to-pay threshold of £20,000/QALY gained.
Conclusions: The FDC tablet of solifenacin 6 mg plus TOCAS provides important clinical benefits and is a
cost-effective treatment strategy in the UK NHS compared with tolterodine plus tamsulosin for men with
both storage and voiding LUTS/BPH.
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The term ‘lower urinary tract symptoms’ (LUTS) is used
to describe a condition that encompasses storage, void-
ing and post-micturition symptoms [1,2]. The aetiology
of LUTS can be multifactorial [2,3], but BPH is a com-
mon cause in men. Storage symptoms (e.g. urgency, fre-
quency, urgency incontinence and nocturia) and voiding
symptoms (e.g. weak or intermittent urinary stream,
straining, hesitancy, terminal dribbling and incomplete
emptying) are common and frequently co-exist in men
with LUTS [4,5]. Storage symptoms represent the most
troublesome LUTS, reported in up to 42% of men aged
≥75 years [4]. Storage symptoms are also reported to be
the most bothersome LUTS [6].
Overall, the recommended treatment options for men
with moderate-to-severe LUTS include α-blockers, 5α-
reductase inhibitors (in those with a large prostate, 30 g
or 40 mL) and antimuscarinic (in those with predomin-
ant storage symptoms) [2,4,7]. In addition, α-blocker
plus antimuscarinic combination treatment should be
considered for patients not adequately responding to
monotherapy of either drug [2,4]. However, the majority
of men with moderate-to-severe LUTS associated with
BPH receive α-blocker monotherapy only [8], whilst
less than 25% are reported to receive an antimuscarinic
[8,9]. Additionally, α-blocker monotherapy is reported
to improve voiding and storage symptoms in men with
LUTS/BPH [10,11]. However, storage symptoms may
persist in some men after receiving α-blocker monother-
apy, epitomised by data from Lee et al. that reported
only 35% of men with storage symptoms were suffi-
ciently controlled by this treatment strategy [12].
Several trials have demonstrated that α-blocker plus
antimuscarinic combination treatment is more effective
than α-blocker monotherapy for men with moderate-to-
severe LUTS and documented storage symptoms
[13-19]. The most recent phase 3 trial (NEPTUNE),
which included 1,334 men with LUTS/BPH who had
moderate-to-severe storage symptoms and voiding
symptoms, showed that solifenacin 6 mg plus an oral
controlled absorption system (OCAS™) formulation of
tamsulosin (TOCAS) improved storage symptoms and
quality of life compared with TOCAS alone [18]. The
combination treatment was also well tolerated and ex-
hibited an adverse event profile similar to that reported
for the individual monotherapies. A once-daily, FDC
tablet of solifenacin 6 mg plus TOCAS 0.4 mg aimed at
treating both storage and voiding symptoms in men with
LUTS/BPH is licensed and available in several countries,
including the UK [20].
The aim of this study was to perform a cost-
effectiveness analysis for a once-daily FDC tablet of
solifenacin 6 mg plus TOCAS (0.4 mg) versus daily tol-
terodine extended release (ER, 4 mg) plus tamsulosin(0.4 mg) given concomitantly, in men with LUTS/BPH
who have moderate-to-severe storage symptoms and
voiding symptoms within the UK healthcare setting.Methods
Model overview
A Markov model was developed to compare the
cost-effectiveness of a FDC tablet of solifenacin 6 mg
plus TOCAS versus tolterodine plus tamsulosin given
concomitantly over an analytical time horizon of 1 year
from the perspective of the UK NHS (Table 1). A
4-week cycle period was employed, the minimum
time interval used to detect treatment differences in
LUTS clinical trials. Inputs for effectiveness data, costs
and utilities were extracted from published sources
and interviews with clinical experts, as described in
detail below. The model provided outcome estimates
for total treatment costs, QALYs and incremental cost-
effectiveness ratio (ICER). The model was programmed
in Microsoft Excel. No ethics or consent were required
for this study.Patients
The model considered men with LUTS/BPH who had
moderate-to-severe storage symptoms and voiding symptoms,
defined by ≥8 micturitions/day and ≥2 urgency episodes/day
(Patient Perception of Intensity of Urgency Scale [PPIUS]
grade 3 or 4 [21]).Treatment pathway
Men entering the model were treated with daily
regimens of FDC tablet of solifenacin 6 mg plus TOCAS
(0.4 mg) or tolterodine ER (4 mg) plus tamsulosin
(0.4 mg) given concomitantly. After a first treatment
period of 4 weeks, men could have experienced a treat-
ment response or no response, based on changes in total
urgency and frequency score (TUFS) of ≥6 or <6 points,
respectively, estimated as the minimally important differ-
ence [22]. TUFS is a validated instrument that captures
storage symptoms (urgency and frequency) in a single
parameter; TUFS is calculated as the sum of the PPIUS
scores (grading of 0 to 4 for each void) recorded in a pa-
tient’s micturition diary divided by the number of days
recorded in the diary [18].
Patients, either with or without a response may
remain on drug or discontinue the treatment (cope with
symptoms or wait for surgery to alleviate symptoms) at
any model cycle (Figure 1). After 12 weeks (three cycles),
patients were permitted to switch to a different combin-
ation regimen. After the first 12 weeks, the treatment
effect was assumed to be stable (no improvement or
deterioration in TUFS).




Markov state transition model incorporating a decision tree




Time horizon 1 year
Cycle length 4 weeks
Patient
population
Men with LUTS/BPH who have moderate-to-severe storage symptoms (≥8 micturitions/day and ≥2 urgency episodes/day*) and
voiding symptoms
Treatments Once-daily FDC tablet of solifenacin 6 mg plus TOCAS 0.4 mg
Tolterodine ER 4 mg plus tamsulosin 0.4 mg daily, given concomitantly
Outcomes Total treatment costs
Quality adjusted life years
Incremental cost-effectiveness ratio
*Patient Perception of Intensity of Urgency Scale, grade 3 or 4.
BPH, benign prostatic hyperplasia; ER, extended release; FDC, fixed-dose combination; LUTS, lower urinary tract symptoms; TOCAS, oral controlled absorption
system (OCAS™) formulation of tamsulosin.
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The model estimated the following outcomes: total treatment
costs; QALYs gained; and ICER. All results are expressed on
a per patient basis.
Model input parameters
Assumptions
Several assumptions were made in the model to reflect
clinical practice (Additional file 1: Table S1). Input was
sought from a group of five clinical experts (two general
practitioners [GPs] and three urologists) from the UK, to
validate the model input parameters for where data were
limited and to fill any data gaps (i.e. surgery, persistence









Figure 1 Patient flow diagram.Transition probabilities
Transition probabilities for FDC tablet of solifenacin
6 mg plus TOCAS during the first three cycles were derived
from the NEPTUNE study (Table 2) [18]. Tolterodine plus
tamsulosin was assumed to have the same treatment effect
as FDC tablet of solifenacin 6 mg plus TOCAS (Additional
file 1: Table S1).
Persistence, switching and surgery
Patients may have discontinued treatment at the end
of each cycle due to adverse events or perceptions of
efficacy (e.g. satisfaction or dissatisfaction with efficacy;
an assumption was made that patients may discontinue




























From response to From no response to
Response No response Response No response
1 0.000 0.000 0.539 0.461
2 0.843 0.157 0.278 0.722
3 0.878 0.122 0.248 0.752
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were derived from a large observational study of UK
primary care between January 2004 and September 2011
(The Health Improvement Network [THIN] database).
The analysis included men aged ≥45 years who had
an initial diagnosis, symptoms or therapies indicative
of LUTS/BPH, and found that over a median follow-
up of 2 years, 43.0% and 59.8% of men discontinued
solifenacin and tolterodine, respectively [8] (Table 3).
In addition, switching rates of 15.3% and 23.3% for soli-
fenacin and tolterodine were reported from the THIN
database.
To accommodate the possibility of surgical treat-
ment in the model, it was assumed that 50% of the
patients who discontinued the treatment would be
eligible for a surgical procedure within 6 months and,
consequently, would discontinue drug treatment [4].
Transurethral resection of the prostate (TURP) was
chosen as the surgical procedure because it is the
current surgical standard procedure for men with
LUTS secondary to BPH [2]. The 6-month probability
of surgery for TURP was converted into a 1-month
probability, assuming that 11% of patients received
surgery every month.Table 3 Discontinuation and switching rates for









6 mg + TOCAS
43.0% 0.023 53.0% 0.031
Tolterodine + tamsulosin 59.8% 0.037 69.8% 0.049
Switching rates
FDC tablet solifenacin
6 mg + TOCAS
15.3% 0.007 15.3% 0.007
Tolterodine + tamsulosin 23.3% 0.011 23.3% 0.011
FDC, fixed-dose combination; TOCAS, oral controlled absorption system
(OCAS™) formulation of tamsulosin.Quality of life
Utility values were derived from EQ-5D data collected in
the NEPTUNE study (Table 4) using the UK tariffs.
Withdrawal and discontinuation were assumed to have
the same utility as the baseline. The average of the re-
sponse and non-response health state was used to calcu-
late the second-line treatment utility weight, as specific
efficacy data were not available. The utility for the post-
surgery health state was derived by combining disutilities
from DiSantostefano et al. [23] and the response utility
value from the NEPTUNE study [18] with the probabil-
ities of improvement, no improvement and adverse
events after surgery [23]. Mapping algorithms were also
used to derive utilities from a disease-specific instrument
overactive bladder questionnaire (OAB-5D) as part of
the sensitivity analysis [Astellas, data on file].
Mortality
The mean age of the men in the model was determined to
be 66 years – consistent with the mean age (65.4 years)
of the randomised men in the NEPTUNE study [18].
The annual mortality probability for the population was
assumed to be the same as that of men aged 66 years
from the UK general population (2008–2010) [24].
Costs and resource utilisation
Costs in the model accounted for the resource utilisation
associated with all primary care and hospital-based treat-
ments. Costs were considered over the whole model
period and were based on the assignment of fixed costs
to health states and transitions between health states
(Table 5). Direct costs included drug acquisition costs,
healthcare professional visits, surgery, hospitalisation
time, and treatment of adverse events. All costs were
based on 2013 prices and expressed in British pounds
(£). Where 2013 unit costs were not available, costs
were adapted to 2013 values using the consumer price
index. Costs and outcomes were discounted at 3.5% per
annum, as recommended by NICE [25].
Drug acquisition costs were obtained from the British
National Formulary [26] taking into account the daily
dose (Table 5). Patients were assumed to have regular
GP/urologist follow-up visits every 6 months; additional
visits were planned for the switching or discontinuation
of treatment. All surgical procedures were assumed to
be TURP based on advice from interviews with clinical
experts.
Sensitivity analyses
Deterministic and probabilistic sensitivity analyses were
performed to determine the influence of uncertainty on the
final results. A standard deterministic univariate sensitivity
analysis was performed on all model parameters, varying
each parameter through a plausible range whilst holding
Table 4 Utility weights per health state
Health state Derivation Utility weight
Baseline Based on average utilities of patients at baseline 0.848
Response Value at Week 12 0.887
No response Value at Week 12 0.870
Second-line treatment Average of response and no response health states 0.879
Withdrawal Assumed to be equal to the baseline utility 0.848
Discontinuation Assumed to be equal to the baseline utility 0.848
Post-surgery Derived by combining response utility value from NEPTUNE
study with disutilities from [23], weighted by probability of
improvement, no improvement and adverse events after surgery [23]
0.839
Death Lowest utility possible 0.000
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overall outcomes and the ICER. Results of these analyses
are presented using a tornado diagram. A tornado diagram
visualises and orders the model parameters from those that
have the highest impact on incremental model results to
parameters that have the lowest impact on incremental
outcomes.
In the probabilistic sensitivity analyses (PSA), parameter
estimates were varied within their uncertainty distributions
that best reflect the nature of each specific parameter.
Aligned with standard methods [27], gamma distributions
were selected for costs, beta distributions for probabilities
and utility values, and a Dirichlet distribution was used for
transitions in the first 12 weeks of the model. Monte Carlo
simulations (n = 1,000) were performed using randomly
selected values from the probability distribution assigned
to each parameter. The results of the PSA are presented
in the form of a graph displaying the results of the 1,000
simulations on the cost-effectiveness plane.
Several scenarios analyses were performed using alterna-
tive discontinuation rates, time horizons and utility values.
The discontinuation scenario analysis utilised an alternative
discontinuation rate for tolterodine, which was based on
a report of prescriptions for antimuscarinic therapies in
the UK [28]. This report indicated that discontinuation for
tolterodine versus solifenacin had a relative ratio of 1:10.
Consequently, an alternative 4-weekly discontinuation rateTable 5 Treatment costs
Treatment Description
FDC tablet solifenacin 6 mg + TOCAS 0.4 mg One tablet per day
Tolterodine 4 mg + tamsulosin 0.4 mg One tablet + one capsule per
GP visit Per clinic consultation lasting
direct care costs, incl. qualifica
Surgery Prostate transurethral resectio
without CC, 20% with major C
*Price parity with solifenacin 5 mg (£0.92/day); Prescription charge excluded from U
20% of LB25F plus 80% of LB25D.
CC, complications and comorbidities; FDC, fixed-dose combination; GP, general prac
of tamsulosin.of 0.026 for tolterodine (46.8% over 2 years) was applied to
the model (compared with 0.037 in the base case model).
In the time horizon scenario, the cost-effectiveness for FDC
tablet of solifenacin plus TOCAS versus tolterodine plus
tamsulosin was calculated over four time horizons of 1, 3, 5
and 10 years. Additionally, the utility values for each health
state were replaced with OAB-5D-derived utility values
(Additional file 1: Table S2).
Results
Base case results
A higher proportion of men treated with the FDC
tablet of solifenacin 6 mg plus TOCAS were still on
their original treatment compared with tolterodine plus
tamsulosin at Week 12 (92.0% versus 87.6%, respectively)
and at 1 year (65.0% versus 50.5%, respectively), and a
higher proportion of men had a response (56.9% versus
54.4% at 12 weeks, and 41.5% versus 32.8% at 1 year).
Additionally, the proportion of men in the post-surgery
health state at 1 year was smaller for the FDC tablet
of solifenacin 6 mg plus TOCAS (6.9%) compared with
tolterodine plus tamsulosin (10.2%) (Table 6).
After 1 year, the FDC tablet of solifenacin 6 mg plus
TOCAS was associated with lower annual per patient
total costs (£860 versus £959, respectively) and increased
QALYs (0.839 versus 0.836) compared with tolterodine
plus tamsulosin (Table 7). The FDC tablet of solifenacinPrice (£) Source
0.92*‡ BNF [26]






2,643.4§ NHS [42]; Antoñanzas et al. [43]
K analysis. ‡Price per day. §Price calculated according to Antoñanzas et al. [43]:
titioner; TOCAS, oral controlled absorption system (OCAS™) formulation
Table 6 Base case results: Distribution of patients across
the health states
Base case scenario FDC tablet solifenacin
6 mg + TOCAS
Tolterodine +
tamsulosin
Patient in HS1 41.46% 32.76%








Patient in post-surgery 6.89% 10.18%
Dead patient 1.48% 1.48%
FDC, fixed-dose combination; HS1, Response health state; HS2, No response
health state; TOCAS, oral controlled absorption system (OCAS™) formulation
of tamsulosin.
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effective and less costly) compared with tolterodine plus
tamsulosin (Table 7).
Sensitivity analyses
The univariate analysis showed that the model was
most sensitive to time horizon, discontinuation/withdrawal
rates, drug cost and EQ-5D-derived utility values (Figure 2).
The FDC tablet of solifenacin 6 mg plus TOCAS remained
dominant (i.e. costs less and generates more QALYs) or
was cost-effective (i.e. ICER below the £20,000 threshold)
compared with tolterodine plus tamsulosin in all parameters
except time horizon.
The PSA showed that the annual per patient mean in-
cremental cost was –£99 (standard deviation [SD], £33)
and the incremental QALYs was 0.0019 (SD, 0.0002),
showing that the FDC tablet of solifenacin 6 mg plus
TOCAS remained dominant compared with tolterodine
plus tamsulosin (mean ICER, −£51,941; Figure 3). At a
willingness-to-pay (WTP) threshold of £20,000 per QALY
gained, the probability that the FDC tablet of solifenacin
6 mg plus TOCAS is cost-effective was 100% versus tolterodine
plus tamsulosin.Table 7 Base case results: cost-effectiveness
FDC tablet solifenacin
6 mg + TOCAS
Tolterodine +
tamsulosin




ICER*‡ – Dominates (−£40,469)
*Per patient at 1 year.
‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY,
quality of life adjusted years; TOCAS, oral controlled absorption system
(OCAS™) formulation of tamsulosin.Scenario analyses
An analysis that used an alternative discontinuation rate
for tolterodine plus tamsulosin, as determined by Wagg
et al. [28], indicated that the FDC tablet of solifenacin
6 mg plus TOCAS remained dominant compared with
tolterodine plus tamsulosin (Table 8). Similarly, a sce-
nario analysis performed using OAB-5D-derived utilities
showed that the FDC tablet of solifenacin 6 mg plus
TOCAS remained dominant compared with tolterodine
plus tamsulosin with larger incremental QALYs (0.0005)
after 1 year (Table 8).
A time horizon analysis up to 5 years showed that the
incremental difference in QALYs and total annual costs
for the FDC tablet of solifenacin 6 mg plus TOCAS
compared with tolterodine plus tamsulosin were propor-
tionally smaller with increasing time (Table 9).
Discussion
There are a few reports of cost-effectiveness of drug
treatment in LUTS, but this study represents the first
cost-effectiveness analysis of a FDC tablet of solifenacin
6 mg plus TOCAS. Overall, the results of this analysis
indicate that the FDC tablet of solifenacin 6 mg plus
TOCAS is a cost-effective treatment option for men
with LUTS/BPH who have moderate-to-severe storage
symptoms and voiding symptoms. The base-case analysis
showed that the FDC tablet of solifenacin 6 mg plus
TOCAS is dominant (i.e. was associated with improved
patient outcomes and lower costs) versus tolterodine
plus tamsulosin over a 1-year time horizon.
The robustness of our cost-effectiveness model is
demonstrated through the results of the univariate and
probabilistic sensitivity analyses, as well as the scenario
analyses. The univariate analysis showed that several of
the main drivers for superior cost-effectiveness of FDC
solifenacin 6 mg plus TOCAS versus tolterodine plus
tamsulosin were inputs related to treatment persistence.
Data from several areas of medicine describe that adher-
ence/persistence with medication is a key driver of cost-
effectiveness [29-32]. Two reports of real-world clinical
practice data in the UK indicate improved persistence
for solifenacin versus tolterodine in men with LUTS/
BPH or overactive bladder (OAB). The THIN database
reported that a lower proportion of men with LUTS/
BPH discontinued and switched treatment (43% and
15%, respectively) compared with tolterodine (60% and
23%, respectively) over a median follow-up of 2 years
[8]. In addition, 35% of patients with OAB were still
receiving solifenacin after 12 months compared with
28% for tolterodine ER [28]. Further analyses should be
conducted to confirm these observations, and various
factors are likely to impact persistence. For example,
solifenacin is reported to provide an improved efficacy
(urgency and micturitions) and tolerability (dry mouth)
Figure 2 Cost-effectiveness Tornado diagram: FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
Figure 3 Cost-effectiveness scatter plot: FDC tablet solifenacin 6 mg
+ TOCAS versus tolterodine + tamsulosin.
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this may contribute to the increased persistence with
solifenacin, resulting in fewer patients discontinuing
medication, reduced switching and/or surgery costs, and
improved quality of life. This is supported by the slightly
better outcomes, QALY gains and lower overall costs, re-
ported in our analysis.
Time and quality of life utility values were also key
drivers of cost-effectiveness in our model. The time hori-
zon analysis showed that the FDC tablet of solifenacin
6 mg plus TOCAS remained dominant at the 3-year
time horizon and within a generally acceptable range of
cost-effectiveness for up to 10 years. The robustness of
our model was also exemplified by data showing that the
FDC tablet of solifenacin 6 mg plus TOCAS remained
dominant when utilities were derived from both generic
(EQ-5D) and disease-specific (OAB-5D) instruments.
These data are underscored by the NEPTUNE study
quality of life data, which reported significant improve-
ments in International Prostate Symptom Score (IPSS)
quality of life and OAB-q health-related quality of life
total and coping, sleep, concern, and social subscores
Table 8 Scenario analyses: cost-effectiveness
Discontinuation analysis OAB-5D analysis










860 942 860 959
Difference – −82 – −99
QALYs* 0.839 0.838 0.835 0.831
Difference – 0.0006 – 0.004
ICER*‡ – Dominates (−£133,473) – Dominates (−£26,143)
*Per patient at 1 year.
‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCAS™)
formulation of tamsulosin.
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pared with TOCAS monotherapy [18].
Data suggest that first-line α-blocker monotherapy
may not adequately control symptoms in men with LUTS
associated with BPH [12]. As such, current guidelines rec-
ommend α-blocker plus antimuscarinic combination as a
treatment option for men with moderate-to-severe storage
symptoms if symptom relief has been insufficient with the
monotherapy of either drug [2,4]. This recommendation
is supported by the results of several large randomised
trials that have reported improved symptoms and
quality of life with combination/add-on therapy com-
pared with α-blocker monotherapy in patients with
LUTS [14,15,17,18,34,35]. However, data from a large
population-based study, THIN, indicate that α-blocker
plus antimuscarinic combination treatment is used
in only a small proportion (~15%) of patients with
LUTS/BPH who have both storage and voiding symp-
toms [8]. Overall, these data suggest that there may be
an unmet need in this patient population, based on
the low use of combination therapy in clinical practice
despite its proven effectiveness in men with LUTS/
BPH who have both storage and voiding symptoms.
This de novo model may have some limitations. First,
due to lack of published data, some assumptions were
made using expert opinion only, including resource use
and the proportion of patients going on to have surgery.
Other key assumptions were required, for example dueTable 9 Scenario analysis: time horizon
FDC tablet solifenacin 6 mg + TOCAS v
1 year




‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quali
formulation of tamsulosin.to the absence of persistence data on FDCs or free
combinations in LUTS, and due to there being no head-
to-head studies for the combinations assessed in the
present study. Additionally, the primary trials for the
combination therapies evaluated in our analysis had
some notable differences in the patient populations and
outcome measures that prohibit an indirect treatment
comparison. Patients in these trials had IPSS ≥12 or 13,
≥2 or 3 urgency episodes/24 hours and ≥8 micturitions/
24 hours. In contrast to NEPTUNE, TIMES had an in-
clusion criterion for overactive bladder symptoms but
not one for voiding symptoms. In addition, the primary
efficacy endpoint in TIMES was the Perception of Treat-
ment benefit question [36] and the secondary endpoints
included bladder diary variables, and change in epi-
sodes/24 hours of urgency urinary incontinence, ur-
gency, total micturitions and night-time micturitions. In
NEPTUNE, the co-primary endpoints were total IPSS
and TUFS.
Second, although the model included tamsulosin, soli-
fenacin and tolterodine, which are commonly prescribed
for men with LUTS [8], other common α-blockers (e.g.
alfuzosin) and antimuscarinics (e.g. oxybutynin) were
not considered in our model. Additionally, although
men with LUTS may receive α-blocker or antimuscarinic
monotherapy, our model was restricted to evaluation of
combination treatment only. Therefore, future models
will be required to compare the cost-effectiveness ofs tolterodine + tamsulosin




ty of life adjusted years; TOCAS, oral controlled absorption system (OCAS™)
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pare other feasible combination therapies.
Third, the model allowed treatment to be discontin-
ued at any cycle (i.e. every 4 weeks), but switching of
treatment was not allowed until 12 weeks; this cut-off
is consistent with the assessment point of several re-
cent large randomised clinical trials in LUTS [14,18].
However, it is feasible that switching could occur be-
fore Week 12 in clinical practice for tolerability, effi-
cacy or other reasons.
Fourth, the switching and discontinuation rates applied
to the model were based on data for antimuscarinics only.
This was because, to our knowledge, there are no published
data reporting the long-term (e.g. ≥1 year) persistence of
α-blocker plus antimuscarinic combination therapy in men
with LUTS/BPH.
There are a limited number of published cost-
effectiveness analyses for combination treatment with
α-blockers plus 5α-reductase inhibitors for men with
BPH [23,37-39], but only one published report of
α-blockers plus antimuscarinic combination therapy in
men with LUTS [40]. The cost-effectiveness analyses in
BPH found that combination treatment appears to be
largely more cost effective than monotherapy [37-39].
Similarly, a secondary analysis of the TIMES study
showed that tolterodine plus tamsulosin appears to be
more cost-effective compared with tolterodine mono-
therapy (dominant) or tamsulosin monotherapy (ICER,
10,381/QALY) in patients with LUTS over a 1-year
time horizon [40]. Consistent with our analysis, the
higher drug acquisition costs of tolterodine plus tamsu-
losin were offset by the improved efficacy (postpone-
ment of surgery) and quality of life benefits with
combination treatment. However, there were some dif-
ferences between these two cost-effectiveness analyses
of combination treatment in LUTS, including that the
TIMES model did not incorporate resources associated
with GP visits.Conclusion
The FDC tablet of solifenacin 6 mg plus TOCAS
has been demonstrated to significantly improve storage
symptoms and quality of life compared with TOCAS
alone in men with moderate-to-severe storage symptoms
and voiding symptoms [18]. This analysis shows that the
FDC tablet of solifenacin 6 mg plus TOCAS is also a
cost-effective treatment strategy compared with toltero-
dine plus tamsulosin for this population of men, from
the perspective of the UK NHS. Overall, these data sug-
gest that the introduction of a FDC tablet of solifenacin
6 mg plus TOCAS offers clinical and financial benefits
for management of men with LUTS/BPH who have both
storage and voiding symptoms.Additional file
Additional file 1: Table S1. Key model assumptions [18,23,28,44-46].
Table S2. Alternative utility weights per health state.
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